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The Pap test diagnosed cervical dysplasia, which could recover to normal or progress to cervical cancer (CC), is an early stage of
cell abnormality before CC. This case-control study analyzed the differences in the risk to develop CC between Chinese medicine
(CM) users and nonusers among women who had ever been diagnosed as having cervical dysplasia. A total of 750 CC patients with
a cervical dysplasia history were collected between 1998 and 2011 from National Health Insurance Research Database, and controls
were women with cervical dysplasia history but did not develop CC. Adjusted odds ratio (aOR) for developing CC was assessed
using multivariable logistic regression after adjusting for age, urbanization of residence, and occupation. The proportion of using
CM among CC patients was lower than that among CC nonpatients, with an aOR of 0.8. By analyzing the relationship between
CC development and the frequency of CM usage, the trend test revealed a significant decreasing trend for developing CC among
high-frequency CM users. Moreover, the most frequently used single herb high-frequency was Rheum palmatum (Da-Huang).The
usage of CMmight be an effective complementary method to prevent uterine cervix from progressing to CC after cervical dysplasia
has occurred.
1. Introduction
Cervical cancer (CC) is a prevailing cancer in women, with
about 528,000 annual cases and 266,000 deaths per year
worldwide [1]. The incidence and the mortality rate depend
on the penetration of CC screening programs, which is the
most important strategy to prevent CC [2]. In Taiwan, the
government launched a nationwide cervical screening pro-
gram in July 1995, and since then, annual Pap smear screening
test has been freely provided to women over 30 years old [3].
By detecting the very early stage abnormal cell changes in
the uterine cervix, which is called “cervical dysplasia,” Pap
smear test reduces the development of invasive CC years later
because of the close follow-up and early management of the
dysplasia [4].
The Pap test diagnosed early stage dysplastic cervix,
including atypical squamous cells of undetermined signif-
icance, low-grade squamous intraepithelial lesion, atypical
squamous cells, and high-grade squamous intraepithelial
lesion, could either recover to normal or progress to CC.
Reported rate of spontaneous regression among cervical
dysplasia ranges from 33% to 60%, and the rate of progression
to invasive CC ranges from 1% to 12%. Therefore, instead
of treatment, close follow-up with repeated Pap tests every
three months and colposcopy biopsy are usually suggested
for cervical dysplasia [5]. When the cervical dysplasia keeps
appearing for 12 months or progresses to the next stage, laser
treatment or endocervical curettage combined with coniza-
tion, are indicated [6]. After local excision, close follow-up is
still needed because there is still recurrent dysplasia that has
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been reported in 0.3% to 23% of women with clear excisional
margins [7, 8].
Chinese medicine (CM) is commonly used as a com-
plementary medicine in the treatment of cancer and has
been reported to reduce side effects and reinforce the effi-
cacy of conventional treatment [9, 10], as well as increase
survival rate of cancer patients [11]. Regarding preventing
cancer, large number of natural products and molecules
extracted from herbs have been shown in laboratories to
be potential to prevent cancer [12]. Theses natural products
were reported to exert the anticancer activity via inhibiting
cancer cell proliferation, arresting cell cycle, inducing apopto-
sis, inhibiting epithelial-mesenchymal transition, regulating
immune function [13], and exerting antioxidative and anti-
inflammatory effects [14] in cell and animal studies. However,
epidemiological literature regarding whether CM prevents
cancer fromhappening is limited.The only large case number
study conducted on the prevention of cancer by CM found
that CMmight prevent tamoxifen-caused endometrial cancer
in breast cancer patients [15]. There is still no concrete
evidence in the literature about whether CM prevents the
development of CC from early stage of cervical dysplasia.
As the most important complementary medicine in Tai-
wan, since 1995CMhave been covered by theNationalHealth
Insurance (NHI), which is a health insurance system estab-
lished by the government [16]. The database released by NHI
contains nationwide medical reimbursement information,
which provides researchers to follow patients for several years
to study patterns, treatments, and prognosis of diseases [17].
In order to investigate the relationship between the devel-
opment of CC from cervical dysplasia and the use of CM,
the present population-based case-control study extracted
women who had ever been diagnosed as cervical dysplasia by
Pap test from the NHI database. Then, the differences in CM
usage between cervical dysplasia patients who consequently
developed CC and who did not developed CCwere analyzed.
2. Materials and Methods
2.1. Study Design and Study Population. This case-control
study used the National Health Insurance Research Database
(NHIRD) released by the Bureau of National Health Insur-
ance. Almost all Taiwanese population joins this NHI pro-
gram, with a coverage ratio of over 99%. NHIRD contained
outpatient and inpatientmedical claims of each insurant from
1997 to 2011. By reason of the Personal InformationProtection
Act, the NHIRD was a second-hand database with identity
number deidentified. Diseases were defined according to
the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) in NHIRD. We collected
CCpatients (ICD-9-CM 180) with a cervical dysplasia history
(ICD-9-CM 622.1) from 1998 to 2011. Patients with CC devel-
opment within three years after the cervical dysplasia diag-
nosis were excluded. The index date was defined as the date
of CC diagnosis. Approximately twofold randomly selected
controls from women with cervical dysplasia but without CC
development were frequency-matched with CC patients on
age stratum (every 5 years, e.g., 20–24, 25–29, and 30–34),
the year of cervical dysplasia diagnosis, and the year of index
date (Figure 1). Patients with CM treatment for more than or
equal to 14 days between the cervical dysplasia date and the
index date were defined as CM users. The demographic con-
founding variables included age (20–39, 40–49, 50–59, and
more than 60 years), urbanization of residence (urban and
rural), and occupation (homemaker, white collar, and blue
collar).
2.2. Statistical Analysis. All analyses were performed using
SAS software version 9.4 (SAS Institute, Cary, NC). A two-
tailed𝑝 value of less than 0.05 was defined to be statistical sig-
nificant. Chi-square test was used to examine the differences
in categorical variables (including age subgroup, urbaniza-
tion, and occupation) between CC patients and controls, and
the 𝑡-test was used to examine the differences in continuous
variables.Odds ratio (OR) and 95%confidence intervals (CIs)
of CC were assessed using multivariable logistic regression
model after adjusting for age, urbanization, and occupation.
The association between the development of CC and the
frequency of CM usage was estimated by dividing CM users
into high-frequency group and low-frequency group. Patients
received CM for more than 30 days per year were defined
as high-frequency users and the others were defined as low-
frequency users. The trend test and multivariable logistic
regression model were used to test the association between
the frequency of CM usage and CC development.
3. Results
3.1. Characteristics of Study Subjects. A total of 750 CC
patients and 1498 CC nonpatients who had been diagnosed
as cervical dysplasia were extracted from the NHIRD, with
the mean age of 56.2 ± 13.2 years (Table 1). There were no
differences in age and urbanization of residence between CC
patients and nonpatients. On the other hand, the proportion
of white collar workers among CC patients was less than
that among CC nonpatients (28.0% versus 37.5%), but the
proportions of blue collar workers (41.9% versus 37.4%) and
homemakers (30.1% versus 25.1%) among CC patients were
higher than CC nonpatients.
3.2. CM Usage between CC Patients and CC Nonpatients.
Compared to CC nonpatients, there was a lower proportion
of CM users among CC patients (19.9% versus 24.0%), with
an aOR of 0.80 (95% CI = 0.64–0.99) after controlling for
age, urbanization of residence, and occupation (Table 2).
Stratification analysis showed that the biggest difference in
CM usage happened in the stratum of patients aged 50–59
years (aOR = 0.66, 95% CI = 0.44–0.99). There were no dif-
ferences in using CM between CC patients and nonpatients
in subgroups of urbanization of residence and occupation.
3.3. Frequency of CM Usage and the Development of CC.
Among CC patients, 80.1% of them were CM nonusers, and
others were CM users, composed of 10.1% of high-frequency
CMusers and 9.73%of low-frequencyCMusers.On the other
hand, among CC nonpatients, 76% were CM nonusers, and
others were CM users, composed of 13% of high-frequency
CM users and 11.0% of low-frequency CM users (Table 3).
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Women with CC in
1998–2011
Exclusion
(1) Without cervical dysplasia
history
(2) With cervical dysplasia over
the past 3 years
CC cohort
Women with cervical
dysplasia
(1) Matching criteria: age (every 5 years),
the year of cervical dysplasia, and
the year of index date
Comparison cohort
NHIRD
(2) Matching ratio: 2 : 1
Figure 1: Flow chart for abstracting study subjects. NHIRD, National Health Insurance Research Database, and CC, cervical cancer.
Table 1: Demographic factors of cervical cancer patients and nonpatients who had ever been diagnosed as cervical dysplasia.
CC patients
𝑁 = 750
CC nonpatients
𝑁 = 1498 𝑝 value∗
𝑛 % 𝑛 %
Age, year 0.99
20–39 72 9.60 144 9.61
40–49 202 26.9 404 27.0
50–59 216 28.8 432 28.8
>59 260 34.7 518 34.6
Mean (SD) 56.2 (13.2) 56.0 (13.2) 0.53
Urbanization 0.07
Urban 424 56.5 906 60.5
Rural 326 43.5 592 39.5
Occupation <0.0001
Homemaker 226 30.1 376 25.1
White collar 210 28.0 562 37.5
Blue collar 314 41.9 560 37.4
∗Chi-square test and 𝑡-test. CC, cervical cancer.
Table 2: Odds ratio for using CM in cervical cancer patients and nonpatients stratified by demographic subgroups.
CC patients CC nonpatients
𝑛 % 𝑛 % aOR (95% CI)
CM usage 149 19.9 359 24.0 0.80 (0.64–0.99)∗
Age, year
20–39 19 26.4 38 26.4 0.98 (0.51–1.89)
40–49 43 21.3 112 27.7 0.71 (0.47–1.06)
50–59 40 18.5 111 25.7 0.66 (0.44–0.99)∗
>60 47 18.0 98 18.9 0.95 (0.65–1.40)
Urbanization
Urban 88 20.8 226 24.9 0.81 (0.61–1.07)
Rural 61 18.7 133 22.5 0.76 (0.54–1.08)
Occupation
Homemaker 41 18.1 86 22.9 0.73 (0.48–1.11)
White collar 43 20.5 152 27.1 0.71 (0.48–1.04)
Blue collar 65 20.7 121 21.6 0.92 (0.65–1.29)
Adjusted for age, urbanization, and occupation. CC, cervical cancer; CM, Chinese medicine. ∗𝑝 < 0.05 in the logistic regression model.
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Table 3: Adjusted odds ratio for using CM in cervical cancer patients and nonpatients among CM nonusers, low-frequency CM users, and
high-frequency CM users.
CC patients CC nonpatients aOR (95% CI)
𝑛 % 𝑛 %
CM nonuser 601 80.1 1139 76.0 1.00
CM users
Low frequency 73 9.73 164 11.0 0.86 (0.64–1.16)
High frequency 76 10.1 195 13.0 0.74 (0.56–0.98)∗
𝑝 for trend 0.03
Adjusted for age, urbanization, and occupation. ∗𝑝 < 0.05 in the logistic regression model.
Table 4: Top ten CM singles and formulas prescribed for high-frequency CM users.
% Days/year Daily dose (g)
Single
Rheum palmatum (Da-Huang) 2.20 67.60 0.51
Salvia miltiorrhiza (Dan-Shen) 1.96 43.98 1.10
Corydalis yanhusuo (Yan-Hu-Suo) 1.89 34.60 1.12
Scutellaria baicalensis (Huang-Qin) 1.88 36.91 0.99
Zizyphi spinosi semen (Suan-Zao-Ren) 1.70 45.20 1.39
Cyperus rotundus (Xiang-Fu) 1.50 44.11 0.96
Fritillaria taipaiensis (Bei-Mu) 1.47 33.81 1.07
Angelica dahurica (Bai-Zhi) 1.33 30.91 1.10
Platycodon grandiflorus (Jie-Geng) 1.21 26.48 0.95
Eucommia ulmoides (Du-Zhong) 1.19 32.33 1.14
Formula
Jia-wei-xiao-yao-san 4.03 67.64 4.21
Chuan-qiong-cha-tiao-san 2.50 44.72 3.92
Ge-gen-tang 1.74 32.35 4.12
Suan-zao-ren-tang 1.67 41.28 3.77
Tian-wang-bu-xin-dan 1.55 43.56 3.67
Du-huo-ji-sheng-tang 1.54 40.27 4.66
Zhi-gan-cao-tang 1.53 42.96 3.51
Shu-jing-huo-xie-tang 1.50 34.45 4.59
Xiang-sha-liu-jun-zi-tang 1.50 43.48 4.02
Ban-xia-xie-xin-tang 1.48 32.41 3.69
Furthermore, the risk of developing CC decreased with the
increase of CM using frequency. CC patients had an aOR
of 0.86 (95% CI = 0.64–1.16) for being low-frequency CM
users and had an aOR of 0.74 (95% CI = 0.56–0.98) for being
high-frequency users (trend test 𝑝 = 0.03), compared to CC
nonpatients (Table 3).
3.4. Prescription Patterns of CM among High-Frequency CM
Users. The top ten most frequently prescribed CM singles
and formulas for CM high-frequency users are listed in
Table 4. The most frequently prescribed CM single was
Rheum palmatum (Da-Huang), dominating 2.20% of the
total CM single prescription, with a mean daily dose of
0.51 g and a mean yearly prescription of 67.6 days. The
second commonly prescribed herb was Salvia miltiorrhiza
(Dan-Shen), dominating 1.96% of total CM single prescrip-
tions, with a mean dose of 1.1 g per day and 43.98 days
per year. The third most frequently prescribed single was
Corydalis yanhusuo (Yan-Hu-Suo), dominating 1.89% of the
total CM single prescriptions, with a mean dose of 1.12 g per
day and 34.6 days per year. The most commonly prescribed
formula was Jia-wei-xiao-yao-san, occupying 4.03% of the
total CM formula prescriptions, with a mean dosage of 4.21 g
per day and 67.64 days per year. The second frequently pre-
scribed formula was Chuan-qiong-cha-tiao-san, dominating
2.50% of the total CM formula prescriptions, with an average
dose of 3.92 g per day and 44.72 days per year. The third
frequently prescribed formula was Ge-gen-tang, accounting
for 1.74% of the total CM formula prescriptions, with a mean
daily dose about 4.12 g per day and 32.35 days per year.
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4. Discussion
It is well known that herbal medicine, including CM, plays an
important role in the treatment of cancer. Herbs used in CM
have been shown to help in the immune function enhance-
ment and survival rate improvement in cancer patients [18,
19]. In order to investigate CM effects on the development
of cancer, this case-control study examined the relationship
between CM utilization and the CC development from
cervical dysplasia. The results revealed that, after cervical
dysplasia has occurred, those who subsequently developed
CC used less CM than those who did not develop CC.
Moreover, the longer the patients took CM, the less the
possibility was for CC development from cervical dysplasia.
Among cervical dysplasia patients, there were no dif-
ferences in age and urbanization of residence between who
developed CC later and who did not develop CC. Otherwise,
there were less proportions of white collar workers, while
there were more proportions of blue collar workers and
homemakers in patients who developed CC. A higher CC
screening participation has been reported among women
with qualified occupation than among women who never
worked [20].This implies a low compliance tomedical follow-
up among homemakers and might explain the high CC
development among homemakers found in this study.
The logistic regression model revealed that, after being
diagnosed with cervical dysplasia, patients who consequently
developed CC used less CM than who did not develop CC,
with an aOR of 0.8. In most of the stratified subgroups,
the aORs for using CM in CC patients ranged from 0.71 to
0.81 compared to CC nonpatients. However, there was no
statistical significance in using CM between CC patients and
nonpatients in almost all subgroups except in the subgroup
aged between 50 and 59. We speculated that the inability to
reveal statistical significance was due to the small case num-
ber of each subgroup after stratification. On the whole CC
patients were less likely to use CM than CC nonpatients after
cervical dysplasia had been diagnosed.The result implied that
CM might play a role in the prevention of CC from cervical
dysplasia. Moreover, the trend test showed that CC patients
had a smaller aOR for using CM high-frequently than
for using CM low-frequently, implying that the prevention
effect might be dose-dependent. As for preventing cancer
by CM, a previous population-based study reported that
CM might prevent tamoxifen-caused endometrial cancer in
breast cancer patients. In that study, among breast cancer
patients who take tamoxifen, CM users were less likely to
develop endometrial cancer thanCMnonusers, with a hazard
ratio of 0.61. [15]. Since there are no other large case number
studies regarding preventing cancers by CM, more future
works on other cancers will be needed.
Among the top ten CM single herbs used by the high-
frequency CM users, Rheum palmatum (Da-Huang) was the
most highly used one. Rheum palmatum (Da-Huang), which
is used to clear heat and resolve toxin by TCM practitioners,
has been shown to possess anti-inflammatory and anticancer
ability [21]. Moreover, a molecular extracted from Rheum
palmatum (Da-Huang), emodin, was found to inhibit the
growth of CC cells by inducing apoptosis through the
intrinsic mitochondrial and extrinsic death receptor pathway
[22].The second frequently prescribed single herb was Salvia
miltiorrhiza (Dan-Shen), which is used to improve the stasis
status, a common condition existing in cancer pathogenesis
according the theory of traditional CM [23, 24]. Salvia
miltiorrhiza (Dan-Shen) has also been found to possess anti-
inflammatory and anticancer activities in several cancer cell
lines, not only via inducing apoptosis of cancer cell but also
via inhibiting the estrogen receptor signal pathway, indicating
it might influence the stimulation of estrogen on CC cells
[25]. The third frequently prescribed single was Corydalis
yanhusuo (Yan-Hu-Suo), which is also used traditionally to
remove stasis and has been found to be with an antiprolif-
erative effect in cancer cells through the combined actions
of its two main compounds, named tetrahydropalmatine
and berberine [26]. The fourth frequently prescribed single
herb was Scutellaria baicalensis (Huang-Qin), from which
baicalein is isolated and has been reported to have the
function of suspending the cell cycle and inhibiting the
proliferation of SiHa and HeLa cervical cancer cells [27]. The
fifth frequently used CM single was Zizyphi spinosi semen
(Suan-Zao-Ren), which is widely used for the treatment
of insomnia. Its active compound, Sanjoinine A, has been
shown to increase sleep rate and sleep time [28]. It has been
reported that sleep disturbance is one of the risk factors
for cancers [29]; therefore, Zizyphi spinosi semen (Suan-Zao-
Ren) might help in the prevention of cancer through its
sedative effect.
The top one CM formula used by CM users in the
present study was Jia-wei-xiao-yao-san, which has been
reported to improve the survival in a variety of cancer
patients [30]. Moreover, Jia-wei-xiao-yao-san is commonly
used as a substitute for hormone replacement therapy to treat
climacteric syndrome, including symptoms of depression,
insomnia, and hot flushes [31, 32]. The second commonly
used CM formula was Chuan-qiong-cha-tiao-san, of which
themain herb isLigusticum chuanxiong (Chuan-qiong).With
its antioxidative function, Ligusticum chuanxiong (Chuan-
qiong) possesses anticancer effects through the induction
of apoptosis and inhibition of DNA damage [33]. The third
frequently used CM formula was Ge-gen-tang, whose major
herb is Puerariae radix (Ge-gen). The main component of
Puerariae radix (Ge-gen), puerarin, has been reported to
decrease the activities of tumor by inhibiting tumor growth
[34] and inducing apoptosis [35]. The fourth and fifth
commonly prescribed CM formulas were Suan-zao-ren-tang
andTian-wang-bu-xin-dan. Both of the formulas are used for
the treatment of sleep disorder in traditional CM, and both
contain the herb of Zizyphi spinosi semen (Suan-Zao-Ren),
which was the fifth frequently prescribed single herb in this
study. Therefore, Suan-zao-ren-tang and Tian-wang-bu-xin-
dan might prevent cancer via a similar mechanism to Zizyphi
spinosi semen (Suan-Zao-Ren). By analyzing the top five CM
singles and formulas used by high-frequency CM users, we
hypothesized that besides herbs that are pharmacologically
proved to possess anticancer activities, herbs that are used to
treat mental symptoms are also important in the prevention
of cervical cancer. This hypothesis could be supported by
the theory that unstable mental status could cause immune
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dysfunction [36]. Moreover, in menopausal women those
herbs that treat menopausal symptoms and stabilize mental
status might decrease the use of estrogen, which is one of the
risk factors for CC [37]. We speculated that this could also be
a reason that CM users were more unlikely to develop CC
compared to CM nonusers, especially among women aged
from 55 to 59 years.
The basic limitation of the present study was the ret-
rospective design, which could only reveal a correlative
association between CC and CM usage, but it cannot show
a causal relationship between these two variables.The second
limitation is that theNHI database is a collection of insurance
reimbursement data, instead of being designed for research.
Therefore, there might be incorrect data and missing data
in the database. Third, the database only records medical
prescription, instead of real medicine taking, so there may
be biases in counting dosage. Fourth, since the national
insurance system did not pay other forms of complementary
medicine, such as Ayurveda, hypnosis, aroma, and home-
opathy, we could not adjust for variables of other types
of complementary medicine. And fifth, although models in
this study have been adjusted for age, urbanization, and
occupation, these confounding factors might still affect the
efficacy of CM. Besides, confounding factors mentioned in
the second, third, and fourth limitations could not been put
into model for adjusting; therefore, there might be bias in
this study. On the other hand, the advantage of this study
design is that a large number of subjects containing the whole
populationwere recruited at the same time.The present study
provided evidence for the fact that the use of CM negatively
correlated with CC development and found possible CM
candidates which might be beneficial to cervical dysplasia
patients.
In conclusion, this case-control retrospective study
showed that, after the dysplasia had been diagnosed, patients
might have less opportunity to progress to CC if they take
CM. Moreover, high-frequency CM users gained even lower
risk of CC than low-frequency users. This study suggested
that the usage of CM might be a complementary method to
prevent the development of CC from cervical dysplasia.
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